Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, DMT +3 moreLSD, psilocybin, DMT, mescaline, 5-MeO-DiPT, DPT show less
DiPT
N,N-diisopropyltryptamine
DiPT (N,N-diisopropyltryptamine) is a synthetic psychedelic of the tryptamine class. It is a structural analog of DMT, distinguished by predominantly auditory rather than visual effects. It activates serotonin receptors in the brain, producing the altered sound perception that defines it.[1]
DiPT (N,N-diisopropyltryptamine) is a synthetic psychedelic of the tryptamine class. It is a structural analog of DMT, distinguished by predominantly auditory rather than visual effects. DiPT is a full 5-HT₂A receptor agonist, producing its effects by disrupting serotonergic processing in auditory cortical circuits.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, DMT +3 moreLSD, psilocybin, DMT, mescaline, 5-MeO-DiPT, DPT show less
First synthesized around 1959, DiPT was tested in humans by Alexander Shulgin beginning in 1975, with results published in 1980.[2] Shulgin's account in TiHKAL (1997) was the primary reference for decades,[3] and the first neural model for its auditory effects appeared only in 2026.[4] DiPT remains rare and is unscheduled in the United States after the DEA withdrew a proposed ban in 2022.
Subjective effects include downward pitch shifting, distorted harmonics, auditory hallucinations, and alien restructuring of familiar sounds. The experience is defined by sound — music and voices become strange while vision stays largely normal, the opposite of a typical psychedelic. Anxiety from the unfamiliar distortions is common, mild physical stimulation accompanies the experience, and the near-absence of visual effects can make the distortions feel pathological rather than drug-induced.
DiPT produces no physical dependence, and no lethal dose has been established.[5] The primary physical danger is combining it with MAOIs — DiPT activates serotonin receptors and slows serotonin clearance, so adding an MAOI risks dangerous serotonin buildup and a life-threatening overheating response.[6] Understanding is extremely limited: what is known comes from self-experimentation, animal studies, and receptor pharmacology, with no controlled clinical trials.
History[edit]
Discovery
DiPT was first synthesized around 1959 as part of a systematic study of N,N-dialkylated tryptamines.citation needed No psychoactive properties were documented at the time. Alexander Shulgin conducted the first human trials beginning in 1975 and published results with Michael F. Carter in 1980 — the first documentation of DiPT's oral activity and unusual auditory effects.[2]
Scientific significance
Shulgin expanded on the compound in TiHKAL (1997), detailing dosage and first-person accounts of pitch distortion.[3] DiPT's auditory selectivity — a psychedelic that reshapes sound rather than vision — made it a pharmacological curiosity. In 2026, Hurst and Bajo proposed the first neural model for this selectivity and suggested potential therapeutic applications for tinnitus.[4]
Research chemical era and regulation
DiPT appeared on research chemical markets in the late 1990s but remained far less prevalent than its 5-methoxy structural analog 5-MeO-DiPT. The DEA proposed Schedule I placement in January 2022 but withdrew the rule that July, leaving DiPT unscheduled in the United States.
The name DiPT follows standard tryptamine abbreviation conventions — "Di" for two identical N-substituents, "i" for isopropyl, "PT" for propyltryptamine — though the compound is technically an isopropyltryptamine, a naming quirk shared with several dialkyl tryptamines. Among psychedelic users, DiPT occupies a niche reputation as "the auditory psychedelic" — sought by those curious about altered sound perception, avoided by those who find distorted music and voices unsettling.
Chemistry[edit]
Structural class
DiPT belongs to the substituted tryptamine family, built on the indole ring system. Its two bulky isopropyl groups on the amine nitrogen resist breakdown by liver enzymes, making it orally active without a co-drug[6] — a property not shared by simpler tryptamines like DMT.
The same bulk reduces its binding strength at serotonin receptors compared to smaller tryptamines, placing it near the upper size limit for active compounds in this class.[7][8]
Molecular properties
| Molecular formula | C₁₆H₂₄N₂ |
| Molecular weight | 244.37 g/mol |
Pharmacology[edit]
Mechanism of action
DiPT activates serotonin receptors in the brain as a full agonist, matching serotonin's own ability to trigger them[1] — the confirmed mechanism behind classical psychedelic effects.[9] It also slows serotonin clearance from synapses, adding a second serotonergic effect that matters for drug interaction risk.[1]
Unlike its structural analog 5-MeO-DiPT, DiPT does not meaningfully engage a second serotonin pathway — a difference that depends on the 5-methoxy group DiPT lacks.[1] DiPT is less potent than smaller tryptamines at serotonin receptors, a consequence of its bulky diisopropyl arms.[7][8]
Pharmacokinetics
DiPT is orally active because its isopropyl groups resist breakdown by the liver enzymes that would destroy simpler tryptamines like DMT.[6][2] Onset takes 30–60 minutes and effects last 3–8 hours.[3] Genetic variation in liver enzymes may cause significant differences in individual response.[6]
Neuroscience[edit]
Auditory cortical selectivity
The central puzzle of DiPT is why it reshapes sound rather than vision. Hurst and Bajo (2026) proposed that DiPT's serotonin receptor activation disrupts the brain's pitch maps in auditory cortex — the ordered system by which neurons are tuned to specific frequencies.[4] The characteristic downward pitch shift is the result.
Theoretical frameworks and plasticity
As a serotonin psychedelic, DiPT is expected to produce brain-wide effects common to the class: increased unpredictability in neural firing, disrupted resting networks, and altered sensory filtering.[5] The occasional cross-modal perceptual effects reported by some users are consistent with serotonin-driven synesthesia.[10]
No neuroimaging studies have been conducted with DiPT in humans. Whether auditory networks are preferentially disrupted relative to visual cortex remains untested. The neural basis for the shift from pitch distortion to full auditory hallucination at higher doses is also uncharacterized.
Subjective Effects[edit]
DiPT's effect profile is unlike any other psychedelic. The sonic environment — music, voices, ambient noise — completely shapes the experience, because sound is profoundly altered while vision stays largely intact. The compound immerses the listener in a world of restructured sound rather than transformed imagery.
Among serotonergic psychedelics, DiPT has no close experiential structural analog. Where psilocybin and LSD reshape the visual field and emotional landscape, DiPT leaves vision untouched and restructures auditory reality instead.[9] Musical training or strong pitch awareness can amplify how salient — and how disorienting — the distortions feel.
First synthesized circa 1959 and tested in humans by Alexander Shulgin beginning in 1975, DiPT entered the published record with a 1980 paper documenting its unusual auditory effect profile.[2] Shulgin's expanded account in TiHKAL (1997) remained the primary human pharmacological source for decades,[3] until the first neural model for DiPT's auditory selectivity was proposed in 2026.[4] DiPT remains a low-prevalence research chemical, unscheduled in the United States after the DEA withdrew a proposed scheduling rule in 2022.
Subjective effects include downward pitch shifting, auditory distortion, harmonic disruption, and auditory hallucinations. The experience is defined by its modality — sound becomes alien while vision remains largely untouched, an inversion of the typical psychedelic signature that leaves users immersed in a world of restructured music, voices, and ambient noise. Anxiety provoked by the unfamiliar auditory alterations and mild physical stimulation are common unsought effects.
DiPT produces no physical dependence and has no established lethal dose[5] — rapid tolerance through downregulation makes compulsive use self-limiting.[6] The primary risk is psychological: auditory distortions can provoke acute distress, and the near-absence of visual effects may lead users to interpret the experience as pathological rather than drug-induced. No controlled clinical trials have been conducted; the current understanding rests on Shulgin's self-experimentation, limited animal studies, and a single receptor pharmacology dataset.
History[edit]
Discovery
DiPT was first synthesized in the laboratory of R.B. Barlow and colleagues circa 1959 as part of a systematic exploration of N,N-dialkylated tryptamine analogues.citation needed No psychoactive properties were characterized in that initial work. Alexander Shulgin conducted the first human trials beginning in 1975, publishing results with Michael F. Carter in 1980 — a paper that documented DiPT's oral activity and its unusual auditory effect profile for the first time.[2]
Scientific significance
Shulgin provided expanded documentation in TiHKAL (1997), detailing synthesis routes, dosage titration across 25–100 mg oral, and first-person accounts of pitch distortion.[3] The compound's unique auditory selectivity — a psychedelic that reshapes sound rather than vision — made it a pharmacological curiosity within the tryptamine series. In 2026, Hurst and Bajo proposed the first neural model for this selectivity, terming the phenomenon "diptogenia" and suggesting potential therapeutic applications for tinnitus.[4]
Research chemical era and regulation
DiPT appeared on research chemical markets in the late 1990s alongside other unscheduled tryptamines, though it remained far less prevalent than its 5-methoxy analogue 5-MeO-DiPT. The DEA proposed Schedule I placement in January 2022 but withdrew the rule that July, directing new scientific evaluation — leaving DiPT in regulatory limbo.
The name DiPT follows standard tryptamine abbreviation conventions: "Di" for the two identical N-substituents, "i" for isopropyl, "PT" for propyltryptamine — though the compound is technically an isopropyltryptamine, not a propyltryptamine, a naming quirk shared with several dialkyl tryptamines. Among psychedelic users, DiPT occupies a niche reputation as "the auditory psychedelic" — a compound sought specifically by those curious about altered sound perception and avoided by those who find the prospect of distorted music and voices unsettling rather than illuminating.
Chemistry[edit]
Structural class
DiPT belongs to the substituted tryptamine family — compounds built on the indole ring system with a 2-aminoethyl sidechain at the 3-position. Its defining feature is the N,N-diisopropyl substitution: both amine hydrogens are replaced by branched three-carbon isopropyl groups. This distinguishes DiPT from DPT (N,N-dipropyltryptamine), which carries straight-chain propyl groups at the same positions.
Molecular properties
| Molecular formula | C₁₆H₂₄N₂ |
| Molecular weight | 244.37 g/mol |
The indole ring is unsubstituted — lacking the 4-hydroxy or 5-methoxy groups found in related tryptamines such as psilocin or 5-MeO-DiPT. The combination of an unmodified ring with bulky N,N-diisopropyl groups gives DiPT a pharmacological profile distinct within the tryptamine series.
Structure-activity relationships
The branching of the isopropyl groups provides steric protection against monoamine oxidase, enabling oral activity without MAOI co-administration — a property not shared by simpler tryptamines like DMT.[7] However, the bulk of the diisopropyl groups also reduces receptor binding strength relative to smaller N,N-dialkyl tryptamines (dimethyl, diethyl), placing DiPT near the upper size limit for pharmacologically active compounds at the 5-HT₂A receptor.[8][9]
Stereochemistry
DiPT contains no chirality centers and exists as a single achiral species. No stereoisomeric considerations apply to its pharmacology.
Pharmacology[edit]
Mechanism of action
DiPT produces its psychoactive effects primarily through activation of the serotonin 5-HT₂A receptor, where it acts as a full agonist — matching or slightly exceeding serotonin's own ability to activate the receptor.[1] This 5-HT₂A activation is the established mechanism for hallucinogen-like effects, confirmed in animal discrimination studies.[10]
Unlike its 5-methoxy structural analog 5-MeO-DiPT, DiPT does not activate 5-HT₁A receptors at pharmacologically relevant concentrations.[1] The 5-methoxy ring substitution appears necessary for 5-HT₁A engagement in this structural series.
Beyond direct receptor activation, DiPT moderately inhibits the SERT — the protein responsible for clearing serotonin from synapses.[1] This adds a second serotonergic component and has implications for interaction risk with other serotonin-active drugs. Activity at dopamine and norepinephrine transporters is negligible.
The size of DiPT's N,N-diisopropyl groups places it near the upper boundary for pharmacologically active tryptamines at 5-HT₂A. Compounds with larger N-substituents show marked reductions in receptor binding,[8] and DiPT is less potent than smaller N,N-dialkyl tryptamines in hallucinogen discrimination assays.[9]
Pharmacokinetics
DiPT is orally active without MAOI co-administration. The bulky isopropyl groups on the amine nitrogen resist breakdown by monoamine oxidase in the gut and liver, allowing the compound to reach the bloodstream intact — a property not shared by simpler tryptamines like DMT.[7][2]
No formal pharmacokinetic studies have been published in humans. The time course of effects — onset within 30–60 minutes, total duration of 3–8 hours depending on dose — provides the only available approximation of absorption and elimination kinetics.[3]
No metabolism studies specific to DiPT exist. Class-level data for tryptamines suggest that genetic variation in liver enzymes (particularly CYP2D6) may produce significant individual differences in response and contribute to drug interaction risk.[7]
Neuroscience[edit]
Auditory cortical selectivity
The central puzzle of DiPT is why a serotonin psychedelic produces predominantly auditory rather than visual effects. Hurst and Bajo (2026) proposed the first mechanistic framework — termed "diptogenia" — in which DiPT's activation of 5-HT₂A receptors preferentially disrupts the brain's tonotopic maps, the ordered representation of pitch in auditory cortex.[4] The model posits that DiPT alters how neurons in auditory cortex are tuned to specific frequencies, producing the characteristic downward pitch shift.
The non-uniform nature of the distortion — single tones perceived relatively normally while complex harmonics become discordant — points to frequency-dependent cortical disruption rather than a simple gain change.
Theoretical frameworks and plasticity
As a 5-HT₂A agonist, DiPT is expected to produce brain-wide effects consistent with the psychedelic class: increased neural entropy, disruption of default mode network integrity, and altered sensory gating.[5] The REBUS (Relaxed Beliefs Under Psychedelics) framework predicts that DiPT loosens the brain's learned expectations about pitch, resulting in aberrant auditory perception.
Serotonergic psychedelics as a class promote structural neuroplasticity,[5] but whether DiPT shares this property has not been tested. The cross-modal perceptual effects occasionally reported are consistent with serotonergic mechanisms for drug-induced synesthesia.[11]
No neuroimaging studies have been conducted with DiPT in humans, leaving fundamental questions unanswered. Whether the auditory selectivity corresponds to measurable differences in regional brain activation — preferential disruption of auditory networks with relative sparing of visual cortex — remains unknown. The neural basis for the dose-dependent transition from pitch distortion to frank auditory hallucination is also uncharacterized.
Subjective Effects[edit]
DiPT's experiential character is unlike any other commonly encountered psychedelic. The near-total dominance of auditory over visual phenomenology means that the sonic environment — music, voices, ambient soundscape — shapes the experience more than visual surroundings. Individual sensitivity varies considerably, and prior musical training or strong pitch awareness may amplify the subjective salience of the distortions. Oral ingestion delivers a gradual, hours-long immersion in altered auditory perception, while smoking compresses the same qualitative character into a brief, intense window.
Among serotonergic psychedelics, DiPT has no close experiential structural analog. Where psilocybin and LSD reshape the visual field and emotional landscape, DiPT leaves vision largely untouched and restructures auditory reality — a dissociation between sensory modalities that is unique within the serotonin 2A receptor agonist class.[10]
Effect Grid
At common doses (30–60 mg oral), DiPT's signature auditory distortion is clearly established. All heard sounds — voices, music, environmental noise — are perceived as lower in pitch than normal. Musical harmonies become discordant as the pitch shift is non-uniform across frequencies; chords that normally sound consonant may become jarring. Auditory enhancement gives way to frank distortion. Thought acceleration and analysis enhancement are reported. Visual effects remain minimal or absent.
Physically, nausea is common during the onset period (30–60 minutes). Stimulation, pupil dilation, spontaneous body sensations, and yawning are typical. Some reports note stomach bloating and gastrointestinal discomfort.
Functional impairment is moderate — conversation becomes difficult as voices sound unfamiliar. The total experience lasts 3–6 hours at this range.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tinnitus · Touch enhancement · Synesthesia · Visual drifting · Color enhancement · Depth perception distortion · Geometry · Auditory hallucinations · Internal hallucinations
Color enhancement · Depth perception distortion · Geometry · Auditory hallucinations · Internal hallucinations
Stimulation · Spontaneous body sensations · Muscle tension · Tingling / electric sensations · Yawning · Dizziness
Yawning · Dizziness
Cognitive flexibility
Timeline
First alerts appear 30–60 minutes after ingestion: a subtle sharpening of auditory perception, mild mood shift, and faint awareness that something has changed. Mild nausea may begin during this phase.
Auditory distortion becomes unmistakable as pitch shifting sets in. Music and voices begin to sound lower than normal. Nausea peaks during this phase.
Maximum auditory distortion: all sounds are pitch-shifted downward, harmonic relationships are disrupted, and complex audio (music, speech) may be unrecognizable. At higher doses, auditory hallucinations emerge. Visual effects remain minimal.
Auditory distortion persists but begins to diminish in intensity. Pitch shifting may become less dramatic. Cognitive effects stabilize.
Auditory perception gradually normalizes. Pitch distortion fades in waves — moments of normal hearing interspersed with residual shifting. Cognitive function returns toward baseline.
Subtle residual effects may persist for 2–4 hours after resolution: mild auditory sensitivity, gentle mood elevation or reflectiveness, and slight wakefulness. Appetite may be suppressed.
⚠ Do not drive or operate machinery for at least 8 hours after ingestion, as residual auditory processing changes may impair situational awareness.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · DMT
Toxicity
No lethal dose has been established for DiPT in any species, and no human fatalities have been attributed to it in the published literature.safety citation needed No case reports of organ damage or serious physical adverse events specific to DiPT appear in tryptamine toxicology reviews.[11][12] This absence of data reflects extremely low prevalence of use — it is not evidence of safety.
Analogue adverse events
The closest relevant case involves 5-MeO-DiPT, DiPT's 5-methoxy structural analog, which caused muscle breakdown and temporary kidney failure in a 23-year-old.[13] DiPT lacks the 5-methoxy group responsible for additional receptor activity, but the case demonstrates that serious organ toxicity is possible within this structural class.
Class-level risks
Tryptamine class risks include rapid heart rate, elevated blood pressure, overheating, muscle breakdown, and serotonin syndrome — described as "considerable" overall harm in a systematic review.[11] Serotonergic psychedelics as a class are considered physiologically safe at typical doses and do not produce dependence,[5] but no DiPT-specific safety data exist.
Psychological risks
The primary acute risk is distress from the unusual auditory distortions. Pitch shifting, harmonic disruption, and auditory hallucinations can be profoundly unsettling, especially for users unfamiliar with DiPT's effects or in environments with complex sound.
The near-absence of visual effects compounds this: users expecting a typical psychedelic may interpret what they hear as pathological rather than drug-induced. Standard serotonin-receptor-mediated risks also apply — anxiety, panic, paranoid thinking, and ego dissolution — with potential for acute psychotic episodes in predisposed individuals.[5]
Tolerance and dependence
Serotonergic psychedelics do not produce physical dependence.[5] Tolerance develops through downregulation of serotonin receptors in the frontal cortex after use,[14][15] and community data suggest full sensitivity resets in approximately 7 days.citation needed
Cross-tolerance with other serotonergic psychedelics — LSD, psilocybin, DMT, and mescaline — is expected through the shared mechanism.[15]
Drug Interactions
Monoamine oxidase inhibitors
Combining DiPT with MAOIs — including prescription antidepressants (phenelzine, tranylcypromine, moclobemide) or natural sources like harmaline — risks serotonin syndrome. DiPT both activates serotonin receptors and slows serotonin clearance; MAOIs block the remaining clearance route, causing dangerous accumulation.
Tryptamine drug interactions "occur additively at the pharmacokinetic and pharmacodynamic levels, leading to severe or even fatal serotonin toxicity".[6][16]
SSRIs and SNRIs
Chronic SSRI or SNRI use may blunt DiPT's effects through receptor downregulation while adding to the total serotonergic load, creating toxicity risk.[6]
Lithium
Lithium combined with classical psychedelics has been associated with increased seizure risk and psychological disturbance.citation needed
Tricyclic antidepressants
Serotonin toxicity risk exists through both direct serotonin potentiation and competition for shared liver enzyme pathways.[16]
Other serotonergic psychedelics
Combining DiPT with other serotonergic psychedelics adds both cross-tolerance and an unpredictable additive serotonergic load.
Contraindications
6 knownNo DiPT-specific contraindication studies exist. The following are inferred from the serotonergic psychedelic class:
- Personal or family history of psychotic disorders — serotonin receptor activation may trigger or worsen psychotic episodes
- Bipolar disorder — risk of triggering manic episodes
- Lithium use — elevated seizure risk in combination with serotonergic psychedelics
- MAOI co-administration — serotonin syndrome risk
- Heart conditions — risk of rapid heart rate and elevated blood pressure from serotonergic stimulation
- Pregnancy — unknown risk to fetal development; no reproductive toxicity data existsafety citation needed
Harm Reduction[edit]
Forms & Identification
DiPT circulates almost exclusively as a powder or crystalline solid, typically the hydrochloride salt. On unregulated markets, the primary concern is verifying that material sold as DiPT is actually DiPT — substitution and mislabeling are significant risks for any low-prevalence research chemical.
Reagent testing can rule out certain classes of substitution but cannot positively confirm DiPT identity. Laboratory analysis is the only way to know with certainty what a sample contains.
Guidelines
- Test all material with reagent kits before use; consider laboratory testing services for definitive identification
- Start with a low dose and allow a full session before redosing — onset can take up to 60 minutes
- Choose a quiet, familiar environment with control over audio playback
- Have a sober sitter present who understands the auditory nature of DiPT's effects
- Avoid complex social settings or live music venues for a first experience — distorted voices and instruments can be disorienting
- Eat lightly 2–3 hours before ingestion to reduce nausea risk
- Keep water accessible and maintain normal hydration throughout
- Clear the following day of obligations — residual auditory effects or fatigue may persist
Set & Setting
Because DiPT's effects are overwhelmingly auditory, the sonic environment matters more than with any other psychedelic. A familiar, controlled listening space — with the ability to change or stop audio — provides far more agency over the experience than a complex or unpredictable soundscape.
Users with strong musical training or absolute pitch may find the distortions more salient and potentially more distressing. A sober sitter who understands DiPT's auditory-specific character is particularly valuable — they can reassure that what is heard is drug-induced and temporary.
Aftercare & integration. Auditory distortions can linger as a subtle perceptual afterglow for several hours after the primary effects resolve. Allow hearing to return fully to baseline before making judgments about any lasting changes. If pitch perception feels altered the day after use, this typically resolves within 24–48 hours.
Journaling the auditory experience shortly after the session can help process what happened. If auditory distortions persist beyond 48 hours or cause significant distress, consult a healthcare provider.
Recovery & Support
DiPT does not produce physical dependence, and compulsive use patterns are self-limiting due to rapid tolerance. If use has become driven by psychological distress rather than curiosity, psychedelic integration therapists and harm reduction organizations such as the Fireside Project (62-FIRESIDE) can provide non-judgmental support. For broader substance use concerns, SAMHSA's National Helpline (1-800-662-4357) offers free, confidential referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most DiPT experiences involve unusual but non-dangerous auditory distortions. Seek immediate help if the person shows signs of serotonin syndrome (tachycardia, high body temperature, muscle rigidity, agitation, confusion), seizures, loss of consciousness, or expresses intent to harm themselves.
Immediate steps:
- 1. Move the person to a quiet, low-stimulation environment
- 2. Stay calm and speak in simple, reassuring sentences
- 3. If unresponsive, place in the recovery position and call emergency services immediately
- 4. If conscious but distressed, remind them that the auditory effects are temporary and caused by the substance
- 5. Do not restrain unless there is immediate danger of self-harm
What to tell the dispatcher: Name the substance (DiPT / diisopropyltryptamine), the amount taken if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
DiPT's legal status is unusual — it remains unscheduled under US federal law despite documented psychoactive effects since 1980, after the DEA withdrew a proposed ban in 2022. Legal status varies internationally, with several jurisdictions capturing DiPT under generic tryptamine provisions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | DEA proposed Schedule I placement (87 FR 2376, January 2022)[17] but withdrew the rule July 2022 (87 FR 45290),[18] directing new HHS scientific evaluation. Potentially subject to the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Captured under the tryptamine generic catch-all clause covering N,N-dialkyl substituted tryptamines; DiPT is explicitly cited as an example compound.[19] |
| Australia | Schedule 9 (Prohibited Substance) | Prohibited under the Poisons Standard. Possession and supply require government licence; research use requires special authorization. |
| Canada | Not explicitly listed | Not specifically scheduled under the Controlled Drugs and Substances Act (CDSA). Status may be subject to interpretation as a tryptamine analogue in enforcement contexts. |
| New Zealand | Class C controlled drug | Scheduled as a tryptamine analogue of DMT under the Misuse of Drugs Act. |
| European Union | No EU-wide scheduling | Not among substances specifically scheduled by the EMCDDA early warning system. Legal status varies by member state. |
Analogue liability
In the United States, DiPT's unscheduled status does not preclude prosecution under the Federal Analogue Act, which treats substances structurally and pharmacologically similar to Schedule I or II drugs as controlled when intended for human consumption. DiPT's structural similarity to DMT (Schedule I) and demonstrated hallucinogenic pharmacology establish grounds for analogue prosecution, though no published federal case law specific to DiPT was identified.
The withdrawn scheduling proposal represents ongoing regulatory interest. A new scheduling recommendation from HHS could arrive at any time.citation needed
Legal status changes frequently and varies by jurisdiction. This is not legal advice — verify current law in your jurisdiction before acting on it.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · DMT
Toxicity
No lethal dose has been established for DiPT in any species, and no human fatalities have been attributed to the compound in the published literature.safety citation needed No case reports of organ damage or serious physical adverse events specific to DiPT were identified in comprehensive reviews of tryptamine toxicology.[12][13]
This absence of adverse event data reflects DiPT's extremely low prevalence of use and limited research attention — it does not constitute evidence of safety. The toxic dose in humans is unknown.safety citation needed
Analogue adverse events
The closest adverse event data comes from 5-MeO-DiPT, DiPT's 5-methoxy structural analog, which caused muscle breakdown and temporary kidney failure in a 23-year-old following ingestion.[14] DiPT lacks the 5-methoxy group responsible for additional receptor activity, but this case demonstrates that serious organ toxicity is possible within the structural class.
Class-level risks
Tryptamine class adverse effects include rapid heart rate, elevated blood pressure, overheating, muscle breakdown, and serotonin syndrome, with overall harm described as "considerable" in a systematic review.[12] Serotonergic psychedelics as a class are considered physiologically safe at typical doses and do not produce dependence,[5] a class-level assessment that applies to DiPT with the caveat that no substance-specific safety data exist.
Psychological risks
The primary acute psychological risk is distress provoked by the unusual auditory distortions. Downward pitch shifting, harmonic disruption, and auditory hallucinations may be profoundly unsettling, particularly for users unfamiliar with DiPT's specific effect profile or in environments with complex auditory input.
This risk is compounded by the near-absence of visual effects — users expecting a typical psychedelic experience may interpret the auditory distortions as pathological rather than drug-induced.
Standard 5-HT₂A-mediated psychological risks also apply: anxiety, panic, paranoid thinking, and ego dissolution with potential for acute psychotic episodes, particularly in individuals predisposed to psychotic disorders.[5] No published cases of Hallucinogen Persisting Perception Disorder (HPPD) have been attributed to DiPT, though this likely reflects under-reporting rather than absence of risk.
Tolerance and dependence
Serotonergic psychedelics are non-dependence-forming.[5] Rapid tolerance development itself limits compulsive use patterns.
Tolerance develops through downregulation of 5-HT₂A receptors in the frontal cortex following activation.[15][6] Community data suggest full sensitivity resets in approximately 7 days,citation needed consistent with class-level receptor downregulation kinetics but unconfirmed by DiPT-specific studies.
Cross-tolerance with other serotonergic psychedelics — including LSD, psilocybin, DMT, and mescaline — is expected through the shared 5-HT₂A mechanism.[6] No published case reports of DiPT dependence or withdrawal exist.
Drug Interactions
Monoamine oxidase inhibitors
Combining DiPT with MAOIs — including pharmaceutical MAOIs (phenelzine, tranylcypromine, moclobemide) and naturally occurring MAOIs (harmaline, as in ayahuasca preparations) — risks serotonin syndrome. DiPT both activates serotonin receptors and inhibits the SERT; adding an MAOI blocks the body's primary route for clearing excess serotonin, creating dangerous accumulation.
Drug interactions with tryptamines "occur additively at the pharmacokinetic and pharmacodynamic levels, leading to severe or even fatal serotonin toxicity".[7][16]
SSRIs and SNRIs
Concurrent SSRI or SNRI use presents a dual interaction: chronic use may blunt psychedelic effects through receptor downregulation, while additive serotonergic load creates toxicity risk. Competition for shared liver enzyme pathways is also possible.[7]
Lithium
Lithium combined with classical psychedelics has been associated with increased seizure risk and psychological disturbance in case reports. This interaction is considered elevated risk based on class-level evidence.citation needed
Tricyclic antidepressants
Serotonin toxicity risk exists through both direct serotonin potentiation and competition for liver enzymes.[16]
Other serotonergic psychedelics
Combining DiPT with other serotonergic psychedelics introduces both cross-tolerance and additive serotonergic load. The net pharmacological outcome is unpredictable.
Contraindications
6 knownNo DiPT-specific contraindication studies have been published. The following are inferred from the serotonergic psychedelic class:
- Personal or family history of psychotic disorders — 5-HT₂A activation may precipitate or worsen psychotic episodes
- Bipolar disorder — risk of triggering manic episodes
- Lithium use — elevated seizure risk in combination with serotonergic psychedelics
- MAOI co-administration — serotonin syndrome risk
- Heart conditions — risk of rapid heart rate and elevated blood pressure from serotonergic stimulation
- Pregnancy — unknown risk to fetal development; no reproductive toxicity data existsafety citation needed
Harm Reduction[edit]
Forms & Identification
DiPT circulates almost exclusively as a powder or crystalline solid, typically the hydrochloride salt. Given its extreme rarity on unregulated markets, the primary identification concern is verifying that material sold as DiPT is actually DiPT — substitution or mislabeling is a significant risk with any low-prevalence research chemical. Reagent testing can help rule out certain classes of substitution but cannot positively confirm DiPT identity; quantitative laboratory analysis provides the only definitive identification.
Guidelines
- Test all material with reagent kits before use; consider laboratory testing services for definitive identification
- Start with a low dose and allow a full session before redosing — onset can take up to 60 minutes
- Choose a quiet, familiar environment with control over audio playback
- Have a sober sitter present who understands the auditory nature of DiPT's effects
- Avoid complex social settings or live music venues for a first experience — distorted voices and instruments can be disorienting
- Eat lightly 2–3 hours before ingestion to reduce nausea risk
- Keep water accessible and maintain normal hydration throughout
- Clear the following day of obligations — residual auditory effects or fatigue may persist
Set & Setting
Because DiPT's effects are overwhelmingly auditory, the sonic environment matters more than with any other psychedelic. A familiar, controlled listening environment — with the ability to change or stop music — provides significantly more agency over the experience than a complex or unpredictable soundscape.
Users with strong musical training or absolute pitch may experience the distortions as more salient and potentially more distressing. Having a sober sitter present who understands DiPT's auditory-specific effects is particularly valuable, as the sitter can provide reassurance that the distortions are drug-induced and temporary.
Aftercare & integration. The auditory distortions produced by DiPT can linger as a subtle perceptual afterglow for several hours after the primary effects resolve. Allow hearing to return fully to baseline before making judgments about any lasting changes. If pitch perception feels altered the day after use, this typically resolves within 24–48 hours.
Journaling the auditory experience shortly after the session — what changed, what was distressing, what was interesting — can help process the unusual perceptual territory DiPT opens. If auditory distortions persist beyond 48 hours or cause significant distress, consult a healthcare provider.
Recovery & Support
DiPT does not produce physical dependence, and compulsive use patterns are self-limiting due to rapid tolerance. If use has become a pattern driven by psychological distress rather than curiosity, psychedelic integration therapists and harm reduction organizations such as the Fireside Project (62-FIRESIDE) can provide non-judgmental support. For broader substance use concerns, SAMHSA's National Helpline (1-800-662-4357) offers free, confidential referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most DiPT experiences involve unusual but non-dangerous auditory distortions. Seek immediate help if the person shows signs of serotonin syndrome (tachycardia, high body temperature, muscle rigidity, agitation, confusion), seizures, loss of consciousness, or expresses intent to harm themselves.
Immediate steps:
- 1. Move the person to a quiet, low-stimulation environment
- 2. Stay calm and speak in simple, reassuring sentences
- 3. If they are unresponsive, place them in the recovery position and call emergency services immediately
- 4. If conscious but distressed, remind them that the auditory effects are temporary and caused by the substance
- 5. Do not restrain unless there is immediate danger of self-harm
What to tell the dispatcher: Name the substance (DiPT / diisopropyltryptamine), the amount taken if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
DiPT occupies an unusual regulatory position: despite documented psychoactive effects published since 1980 and nearly five decades of known existence, it remains unscheduled under federal law in the United States following withdrawal of a proposed scheduling rule. Legal status varies internationally, with several jurisdictions capturing DiPT under generic tryptamine scheduling provisions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | DEA proposed Schedule I placement (87 FR 2376, January 2022)[17] but withdrew the rule July 2022 (87 FR 45290),[18] directing new HHS scientific evaluation. Potentially subject to the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Captured under the tryptamine generic catch-all clause covering N,N-dialkyl substituted tryptamines; DiPT is explicitly cited as an example compound.[19] |
| Australia | Schedule 9 (Prohibited Substance) | Prohibited under the Poisons Standard. Possession and supply require government licence; research use requires special authorization. |
| Canada | Not explicitly listed | Not specifically scheduled under the Controlled Drugs and Substances Act (CDSA). Status may be subject to interpretation as a tryptamine analogue in enforcement contexts. |
| New Zealand | Class C controlled drug | Scheduled as a tryptamine analogue of DMT under the Misuse of Drugs Act. |
| European Union | No EU-wide scheduling | Not among substances specifically scheduled by the EMCDDA early warning system. Legal status varies by member state. |
Analogue liability
In the United States, DiPT's unscheduled status does not preclude prosecution under the Federal Analogue Act, which treats substances "substantially similar" in chemical structure and pharmacological effect to Schedule I or II controlled substances as controlled when intended for human consumption. DiPT's structural similarity to DMT (Schedule I) and demonstrated hallucinogenic pharmacology establish the predicates for analogue prosecution, though no published federal case law specific to DiPT was identified.
The withdrawn scheduling proposal represents ongoing regulatory interest. The HHS review process initiated following the 2022 withdrawal could result in a new scheduling recommendation at any time.citation needed
Frequently asked questions
What is DiPT?
DiPT is a substituted tryptamine psychedelic distinguished by predominantly auditory rather than visual effects. It acts as a G-protein-biased 5-HT₂A full agonist, first evaluated in humans by Alexander Shulgin in 1975.
How long does DiPT last?
Total duration by route of administration — Oral: 3 – 8 hours; Smoked: 15 – 60 min. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for DiPT?
Psychedex publishes a dosage table for DiPT on this page covering these routes of administration: oral, smoked. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with DiPT?
The highest-severity documented interactions for DiPT: MAOIs (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Dopamine agonists (Dangerous), DXM (Dangerous), GHB, Baclofen (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is DiPT addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for DiPT: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, psilocybin, DMT, mescaline, 5-MeO-DiPT, DPT. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcdBlough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (2014) Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. — Psychopharmacology doi:10.1007/s00213-014-3557-7
- [2] ^abcShulgin AT, Carter MF (1980) N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. — Communications in Psychopharmacology PMID:6949674
- [3]
- [4] ^abcHurst A, Bajo VM (2026) N,N-Diisopropyltryptamine and diptogenia: proposed mechanisms for a frequency-selective pitch-distorting psychedelic — Brain Communications doi:10.1093/braincomms/fcag093
- [5]
- [6]
references
- [1] ^abcdBlough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (2014) Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. — Psychopharmacology doi:10.1007/s00213-014-3557-7
- [2] ^abcShulgin AT, Carter MF (1980) N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. — Communications in Psychopharmacology PMID:6949674
- [3]
- [4] ^abcHurst A, Bajo VM (2026) N,N-Diisopropyltryptamine and diptogenia: proposed mechanisms for a frequency-selective pitch-distorting psychedelic — Brain Communications doi:10.1093/braincomms/fcag093
- [5]
- [6] ^abcde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170